Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on May 01, 2011 6:39pm
341 Views
Post# 18515043

all is well (PCA3)

all is well (PCA3)Its clear by the reaction that a # of investors did not like that added uncertainty that the GPRO rumors bring on. I have been out of town all week and listened to a replay of the GP call on Thursday. My take is that in the near term we need to get over $1.00 and jump quickly over $2.00. Might sound like alot but if I would have told you a week ago when GPRO was $60 that they would cross the $84 mark you would have said I am crazy. What frustrates me is that this is CUR's partner making these moves based on their strong pipeline that includes PCA3.
     They could be looking for a partner or some other type of deal; seems like they have been making good money so I am not sure of the motive but a large company moving in could pump the oncology segment full of cash and get PCA3 off to the races. Remember that they are new to this area and might be looking for additional marketing and a sales team outside of their core market. They hired a new gentleman last September who can handle this so I don't believe this is a good reason.
     From what I am hearing from urologists that have used PCA3 for some time now, they believe that it will be rapidly adopted after FDA approval with sales >100 million. I do believe this and I think Panther will take the marker to the next level but will not be hurt initially because its not on the platform.
     I am shocked by where we sit but it is nothing that a good piece of news can't cure. I have said it before that this is how the stock tends to trade just prior to news. Down 3-5% on 4,000 shares. Lets get a pop on big volume to shake up the deck and get moving on.
Bullboard Posts